Vaccines and monoclonal antibodies are reducing RSV hospitalizations, but high costs and limited access in low-income ...

Respiratory syncytial virus is the leading cause of hospitalization among U.S. infants. A vaccine, nirsevimab, can reduce the ...

The death comes as multiple infectious diseases are surging throughout the US, including the 10th wave of the COVID-19 ...

Nirsevimab demonstrated 89% effectiveness against medically attended RSV-associated acute respiratory illness and 93% effectiveness against RSV-associated hospitalizations, although only 442 ...

In a new study, the RSV drug nirsevimab was 93% effective at preventing young children from being hospitalized for the respiratory infection. A new RSV drug designed to protect young children was ...

As the respiratory illness season begins, cases of respiratory syncytial virus (RSV) cases are rising in Canada. But new tools offers hope for prevention.

This analysis documented the continued high burden of medically attended respiratory syncytial virus (RSV)-associated acute respiratory illness among young children in the U.S. Nirsevimab and ...

RSV cases drop in Alaska's Yukon-Kuskokwim region, Ketchikan airport parking is tight, hunters urged to try lead-free ammo, ...

The new research, published Monday (Dec. 9) in the journal JAMA Pediatrics, focused on nirsevimab (Beyfortus), a drug approved in 2023. The medicine, which is given as an injection, uses lab-made ...

RSV prevention among children, including nirsevimab and the maternal RSVpreF vaccine, may be associated with a reduction in ...